Immunome Inc., a biotechnology company specializing in targeted cancer therapies, reported its financial results for the first quarter of 2025. The company recorded a net loss of $41.6 million for the quarter ended March 31, 2025. Research and development expenses totaled $36.9 million, which included $2.4 million in stock-based compensation costs. General and administrative expenses were reported at $10.7 million, with $3.3 million attributed to stock-based compensation expense. As of March 31, 2025, Immunome's cash, cash equivalents, and marketable securities amounted to $317.3 million. This includes net proceeds of $161.7 million from the January 2025 financing, and approximately $11 million in payments related to non-recurring IM-1021 milestones and 2024 annual performance bonuses. The company anticipates that its current cash position will support its operations into 2027. On the operational front, Immunome remains on track to share topline data for the RINGSIDE trial of varegacestat in the second half of 2025. The dose escalation portion of the Phase 1 clinical trial of IM-1021 is ongoing, and the company plans to start a clinical trial for IM-3050, following its IND clearance, in the second half of 2025. Additionally, Immunome is advancing IND-enabling work for its preclinical ADCs, IM-1617, IM-1340, and IM-1335, all incorporating the HC74 inhibitor.